
News|Articles|June 2, 2019
- Pharmaceutical Technology-06-02-2019
- Volume 43
- Issue 6
Supply Chain Risk and Security Maturity Evolution
Discussing supply chain risk and security as a business led journey, Roddy Martin, chief digital strategist at TraceLink, explains the five stages of its evolution.
Advertisement
Discussing supply chain risk and security as a business led journey, Roddy Martin, chief digital strategist at TraceLink, explains the five stages of its evolution to Pharmaceutical Technology:
- "Stage 1. Reacting to risk and security problems after the fact.
- Stage 2. Specialized security and risk management projects; for example, track and trace/serialization.
- Stage 3. Supply chain risk and security are a functional excellence capability; for example, risk and security requirements are codified into all work within functions like manufacturing, procurement, logistics, and so on.
- Stage 4. Supply chain and risk are codified as core ‘this is how we work’ requirements in all horizontal, end-to-end, and cross-functional processes from the patient all the way back through the business into all elements of supply.
- Stage 5. Risk and security capabilities are embedded into and across the total ecosystem and network both internal and external to a company; the core capability is that product integrity, availability, and patient safety are regarded as a given. In stage 5, risk and security are both driven as value based capabilities rather than seen as a cost.”
Article Details
Pharmaceutical Technology
Vol. 43, No. 6
June 2019
Page: 45
Citation
When referring to this article, please cite it as F. Thomas, “Supply Chain Risk and Security Maturity Evolution,” Pharmaceutical Technology 43 (6) 2019.
Articles in this issue
over 7 years ago
Hovione Technology Develops Blister-Based Inhalerover 7 years ago
Enabling Technologies Advance Poorly Soluble Highly Potent APIsover 7 years ago
Pharma Facilities Still Have a Lot to Learnover 7 years ago
Filling the Early Intermediate Security Gapover 7 years ago
As Easy as ABC?over 7 years ago
Regulating Cannabis-Based Medicines in Europeover 7 years ago
On the Right Trackover 7 years ago
Looking Beyond the Solubility Horizonover 7 years ago
Enhancing Bioavailability with Hot-Melt ExtrusionAdvertisement
Related to this article

Science, circularity, regulation, and technology are reshaping how the industry develops packaging for medicines.

The FDA expanded Anktiva to BCG-unresponsive papillary-only NMIBC using existing CIS trial data, a precedent with implications for development timelines and supply planning.

FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.

FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.

Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.

Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.

FDA final guidance defines when companion app output counts as drug labeling and when device-connected or standalone apps belong in prescribing information.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
3
Nitrosamine Problems and Industry Solutions: PharmTech Explained
4
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
5
